Cic edizioni internazionali
Functional Neurology

Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey

Original Article, 253 - 258
doi: 10.11138/FNeur/2013.28.4.253
Tag this article
Abstract
Enhanced HTML Full text PDF
The aim of this survey was to provide an overview of important issues relating to therapeutic strategies based on botulinum toxin type A injection for the treatment of patients with neurological disorders.
Two hundred and ten physicians from neurology and neurorehabilitation units in Italian hospitals answered a questionnaire exploring some clinical aspects of the use of botulinum toxin type A in patients with spasticity/dystonia. 66% of the physicians treated patients with dystonia, 80% treated adults with spasticity, and 35% treated children with cerebral palsy.
Palpation with no instrumental guidance was the injection technique most commonly used for treating patients with dystonia, spasticity and cerebral palsy; 57% of the physicians evaluated patients instrumentally before toxin injection, while 45% assessed postinjection improvements by instrumental means; 78% of the physicians prescribed (when appropriate) rehabilitation procedures after toxin injection. Our results seem to show that the routine use of botulinum toxin in clinics is far from standardized.

Vol. XXXII (No. 3) 2017 July/September

  1. Rethinking dementias
    Sinforiani E., Cotta Ramusino M., Costa A.
  2. Electrodiagnostic and nerve ultrasonographic features in upper limb spasticity: an observational study
    Picelli A., Tamburin S., Berto G., Chemello E., Gandolfi M., Saltuari L., Waldner A., Smania N.
  3. Nociceptive blink reflex habituation biofeedback in migraine
    de Tommaso M., Delussi M.
  4. Recovery from vegetative state of patients with a severe brain injury: a 4-year real-practice prospective cohort study
    Baricich A., de Sire A., Antoniono E., Gozzerino F., Lamberti G., Cisari C., Invernizzi M.
  5. Obstructive sleep apnea syndrome in Parkinson’s disease and other parkinsonisms
    Crosta F., Desideri G., Marini C.
  6. Pisa syndrome in Parkinson’s disease: electromyographic quantification of paraspinal and non-paraspinal muscle activity
    Geroin C., Squintani G., Morini A., Donato F., Smania N., Gandolfi M. G., Tamburin S., Fasano A., Tinazzi M.
  7. Quantitative, functional MRI and neurophysiological markers in a case of Gerstmann-Sträussler-Scheinker syndrome
    Marino S., Morabito R., De Salvo S., Bonanno L., Bramanti A., Pollicino P., Giorgianni R., Bramanti P.
  8. Analysis of Italian regulations on pathways of care for patients in a vegetative or minimally conscious state
    Sattin D., De Torres L., Dolce G., Arcuri F., Estraneo A., Cardinale V., Piperno R., Zavatta E., Formisano R., D'Ippolito M., Vassallo C., Dessi B., Lamberti G., Antoniono E., Lanzillotti C., Navarro J., Bramanti P., Marino S., Zampolini M., Scarponi F., Avesani R., Salvi L., Ferro S., Mazza L., Fogar P., Feller S., De Nigris F., Martinuzzi A., Buffoni M., Pessina A., Corsico P., Leonardi M.
Last Viewed articles: la lista degli ultimi x visitati.
  1. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey
    Smania N., Colosimo C., Bentivoglio A.R., Sandrini G., Picelli A.
    doi: 10.11138/FNeur/2013.28.4.253
credits